Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Verapamil
Drug ID BADD_D02348
Description Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina,[L8791] and was the first calcium channel antagonist to be introduced into therapy in the early 1960s.[A188514] It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications.[L8791] Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate.[A188435]
Indications and Usage For the treatment of hypertension, angina, and cluster headache prophylaxis.
Marketing Status Prescription; Discontinued
ATC Code C08DA01
DrugBank ID DB00661
KEGG ID D02356
MeSH ID D014700
PubChem ID 2520
TTD Drug ID D0R0FE
NDC Product Code 70966-0029
Synonyms Verapamil | Iproveratril | Cordilox | Dexverapamil | Verapamil Hydrochloride | Hydrochloride, Verapamil | Finoptin | Izoptin | Isoptine | Isoptin | Lekoptin | Calan | Falicard
Chemical Information
Molecular Formula C27H38N2O4
CAS Registry Number 52-53-9
SMILES CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
Sudden cardiac deathPotassium voltage-gated channel subfamily KQT member 1P51787T495269927398; 10810773; 10082151; 10408028
Sudden cardiac deathSodium channel protein type 5 subunit alphaQ14524T397169927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily E member 1P15382Not Available9927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily H member 2Q12809T202519927398; 10810773; 10082151; 10408028
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gingival hyperplasia07.09.03.002--Not Available
Gynaecomastia05.05.02.003; 21.05.04.003--
Headache17.14.01.0010.001077%
Heart rate decreased13.14.04.0010.000169%Not Available
Hepatitis09.01.07.004--Not Available
Hepatotoxicity12.03.01.008; 09.01.07.009--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.001077%
Hyperhidrosis08.01.03.028; 23.02.03.0040.000431%
Hyperkalaemia14.05.03.0010.000646%
Hyperkeratosis23.01.01.001--
Hyperkinesia17.01.02.008--Not Available
Hyperprolactinaemia05.03.01.002--Not Available
Hypersensitivity10.01.03.0030.000431%
Hypertension24.08.02.0010.000431%
Hypertrophic cardiomyopathy03.07.02.004; 02.04.01.002--Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.000431%
Hypotension24.06.03.0020.004737%
Hypoxia22.02.02.0030.001077%
Ileus07.13.01.001--
Ileus paralytic07.02.05.001--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intermittent claudication24.04.03.001--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Joint swelling15.01.02.004--Not Available
Lactic acidosis14.01.01.0020.000861%Not Available
Laryngospasm22.04.02.002--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages